Chandra Bhagat Pharma (CBPL) Q2 FY27 Profit Holds Firm Even as Revenue Dips 12%
The pharmaceutical marketer posted a 208% yearly revenue surge but saw a sequential dip, with profit margins improving on cost management.
Chandra Bhagat Pharma's Q2 FY27 profit held steady at ₹3 crore despite a 12% sequential revenue drop. A sharp yearly growth of 208% shows a strong recovery, supported by margin improvement and debt reduction.
For a pharmaceutical marketer reliant on trading growth, Chandra Bhagat Pharma’s latest quarter shows a business in transition. Revenue fell from the prior quarter's high, but profit held firm as margins improved and debt fell.
The numbers tell a story of recovery and consolidation. Revenue of ₹80 crore is down 12% from the March quarter but up a staggering 208% from a weak year-ago base. Net profit stayed flat sequentially at ₹3 crore, but the net profit margin rose 50 basis points to 3.8%.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ2 FY27 (Sep 2026) | PreviousQ4 FY26 (Mar 2026) |
|---|---|---|
| Revenue (₹ Cr) | 80.0 | 91.0 |
| Profit (₹ Cr) | 3.0 | 3.0 |
| Net Profit Margin (%) | 3.8 | 3.3 |
The Margin Story Behind Flat Profit
The flat profit masks a positive shift. While revenue dipped, total expenses fell 11% sequentially, showing tighter cost control. The company's half-year results, reported by mcapital.in, show a pre-tax profit margin of 4.39%, up from 3.53% in FY26, indicating operating leverage is kicking in.
This margin resilience allowed profit to hold steady even as sales softened from the prior quarter's peak. The year-on-year comparison is stark, with net profit margin up 380 basis points from zero.
A Liquidity Trade-Off
Strong growth has come with a cash flow trade-off. According to a report from scanx.trade, operating cash flow turned negative ₹1.97 crore in H1 FY27, driven by a sharp reduction in trade payables. This suggests the company is paying suppliers faster, tightening its working capital cycle even as revenue runs higher.
Simultaneously, the balance sheet is deleveraging. The same mcapital.in analysis notes borrowings fell in the half-year, with net debt estimated to decline further. The company is funding growth while reducing leverage, a positive sign for financial stability.
The Outlook from a Low Base
The half-year revenue of ₹80 crore already represents 69% of last year's full-year sales. This run-rate, highlighted by mcapital.in, implies a potential 40% revenue growth for FY27 if the second half performs similarly. Profit could potentially double from the FY26 level of ₹3.05 crore.
No formal management guidance was found in the research for the full year. The market's immediate reaction, per marketsmojo.com, was neutral, with the stock price unchanged at ₹60 following the announcement.
Key Points
- Profit remained steady at ₹3 crore quarter-on-quarter despite a 12% revenue dip, as net profit margin improved to 3.8%.
- Year-on-year growth is explosive, with revenue up 208% from a very low base in Q2 FY26.
- The company is managing a liquidity shift, with operating cash flow turning negative due to faster payment of suppliers, while simultaneously reducing debt.
- Half-year revenue is already 69% of FY26's total, setting the stage for significant full-year growth if momentum holds.
Hexa Perspective
Chandra Bhagat Pharma’s quarter reveals a firm navigating post-recovery consolidation. The flat profit on lower sales suggests underlying profitability is strengthening, a crucial step for a trading-heavy model. The cash flow squeeze from paying down payables is a near-term cost for a healthier balance sheet. The sustainability of the growth story now hinges on whether the H1 revenue run-rate was a one-time catch-up or a new normal. With a trailing P/E of 14.3, a steep discount to the industry average of 52.2, the market is pricing in significant skepticism about that durability. The next quarter will show if the margin gains and deleveraging can continue alongside top-line stability.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.
